Lonza to manufacture Alector’s mAb drug candidates for Ph I trial
Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.
Archives for May 9, 2019
Takeda divests eye product to Novartis for $5.3bn
Takeda begins the process of divesting products to make its purchase of Shire viable, with $5.7bn worth of assets heading out of the door.
Samsung Biologics to provide CDMO support for ‘bio-venture’ firm GI Innovation
Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.
LabCorp joins $3m investment round for 3D cell culture tech firm Kiyatec
LabCorp participated in a $3m Series B2 financing round for Kiyatec, which is developing ex vivo 3D cell culture technology to help model and predict cancer patients’ response to drug therapies.
Elligo raises $20m to help close clinical research and health care gap
Elligo Health Research raises $20m in Series C funding to expand into more states, as part of the company’s goal to connect more physicians and their patients to clinical trials.
NEWS IN BRIEF
Nimble leaves Roche to commercialize chemical synthesis technology
Nimble Therapeutics spun out from parent company Roche to commercialize its chemical synthesis technology for drug discovery and development.